HI
BHVN

HBK Investments’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

HBK Investments’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,550,000
Closed -$537M – 391
2022
Q3 		$537M Buy
3,550,000
+2,725,000
+330% +$404M 3.8% 3
2022
Q2 		$120M Buy
+825,000
New +$105M 0.67% 10
2019
Q3 		– Sell
-80,000
Closed -$3.5M – 817
2019
Q2 		$3.5M Buy
+80,000
New +$4.51M 0.03% 290

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

HBK Investments's BHVN Position: Q4 2022 in Review

HBK Investments sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 3,550,000 shares — an estimated $537M sold.

HBK Investments first reported a position in BHVN in Q2 2019 and held it in 3 quarters. The position peaked at $537M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • HBK Investments reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • HBK Investments sold 3,550,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $537M.
  • HBK Investments first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 3 quarters.
  • HBK Investments's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $537M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on HBK Investments's 13F filing for Q4 2022, filed 14 Feb 2023.